Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Tykerb – Dual Tyrosine Kinase Inhibitor

Drug (Brand/Generic)

Tykerb/Tyverb/Lapatinib ditosylate

Company/Licensee

GlaxoSmithKline

Therapy Class

TKI

Product Description

Dual-acting TKI that targets erbB1 and erbB2

Current Indication

Breast cancer

Market Sector

Oncology

Development Status

Approved US and Europe
Expand
Close
Close
Close

Go Top